SCHEMBL3653447

SCHEMBL3653447

O=C(Nc1cncs1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.53
BCAT2 O15382 1/20 0.53
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
TP53 P04637 3/20 0.50
MAPT P10636 2/20 0.50
NFKB1 P19838 2/20 0.50
NFKB2 Q00653 2/20 0.50
RELA Q04206 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NAMPT P43490 2/20 0.50
KDM4D Q6B0I6 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
JAK2 O60674 1/20 0.50
TYK2 P29597 1/20 0.50
GAA P10253 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28954592 0.86 GAA (0.55) CSF1RRAB9ATP53MAPTSMN1; SMN2
SCHEMBL7553959 0.85 AQP4 (0.61) MAPTSMN1; SMN2ALOX15MEN1KMT2A
SCHEMBL12700219 0.82 ALDH1A1 (0.53) CSF1RRAB9AMAPTKDM4DKDM4C
SCHEMBL6984067 0.74 RIPK1 (0.52) BCAT2NPC1RAB9ATP53MAPT
SCHEMBL29074245 0.73 NSUN3 (0.55) CSF1RNPC1RAB9ATP53MAPT
SCHEMBL3559655 0.73 MEN1 (0.60) NPC1RAB9ATP53MAPTNFKB1
SCHEMBL31058213 0.72
SCHEMBL1110180 0.71 MDM4 (0.73) NPC1RAB9ATP53MAPTMEN1
SCHEMBL28777345 0.70 ALDH1A1 (0.58) BCAT2NPC1RAB9AMAPTNAMPT
SCHEMBL1685094 0.70 SMN1; SMN2 (0.59) CSF1RNPC1RAB9ATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP claimed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO claimed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed
US-20080312206-A1 Chemical Compounds-149 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312206-A1 Chemical Compounds-149 CSF3R, CSF1R, FLT3 CSF1R 2/4885BCAT2 1692/4885NPC1 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.